Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
According to 3 multicenter, randomized, double-blind, placebo-controlled obesity trials (BMI 30, or BMI 27 with at least 1 comorbidity of hypertension, dyslipidemia, or type 2 diabetes) conducted to evaluate the effect of CONTRAVE in conjunction with reduced caloric intake and increased physical activity, the average percentage of weight loss in patients at 56 weeks ranged from 3.7% to 8.1% with CONTRAVE, compared to 1.3% to 4.9% with placebo
Unlike older compounds in the same class, it has relatively little activity on: Cortisol secretion Prolactin secretion Appetite stimulation This selectivity is one reason it remains popular in peptide protocols
The published record therefore reflects a proof-of-concept study that generated human safety and tolerability data while not meeting its primary endpoint as defined at the studied dose and population
/assets/images/provider/photos/2773575.png)
Given the multisystemic nature of MASLD, multidisciplinary collaboration bringing together hepatologists, endocrinologists, cardiologists, and primary care physicians, is essential to optimize patient care
US$ 24.71
US$ 20.26
US$ 20.54
US$ 21.90
US$ 21.06
US$ 26.02
US$ 29.59
